Clinical Trial Search

Primary: Number of Participants With Adverse Events — 20 participants

Primary: Number of Participants With Local Injection Site Reaction by Severity — 12; 1; 8; 2 participants

Primary: Cmax: Maximum Observed Serum Urate Concentration — 6.6; 6.4 mg/dL

Primary: Area Under the Concentration-time Curve From Zero to Infinity (AUC [0-infinity]) — 1020; 881 μg*day/mL

Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 5; 3; 10; 8 Participants

Primary: Percentage of Participants Who Experienced at Least 1 Treatment-Emergent Adverse Event — 50.0; 50.0; 33.3; 66.7 percentage of participants

Primary: Area Under the Plasma Concentration-time Curve (AUC) From Time Zero to Infinity (AUC0-inf) Adjusted for the Actual Administered Dose (AUC0-inf, Adj) of L-Praziquantel…

Primary: Dose Limiting Toxicity (DLT) — 8; 23; 2 participants

Primary: AUC(0-tlast) [Area Under the Concentration-time Curve After Single (First) Dose From Time Zero to the Last Data Point >LLOQ (Lower Limit of Quantification)] for…

Primary: Pharmacodynamic: Change From Baseline in Mean 24-hour Plasma Glucose (AUC/Duration) at Week 4 (Part 1 - United States) — -4.27; 0.13; -53.8 mg/dL — p=0.5269

Primary: Change From Baseline in D. Farinae HDM-specific IgG4 Antibodies in Serum at 12 Weeks (Part 2) — 0.392; 0.166 Fold Change — p=0.003

Primary: Percentage of Participants Who Experienced At Least One Adverse Event (AE) — 56.9; 53.8; 43.1 Percentage of participants

Primary: Area Under the Curve of Rosuvastatin From 0 to the Last Quantifiable Data Point (AUC0-tz) — 81.5; 87.8; 88.7; 126 nanomol (nmol) * hour (h) / Litre (L)

Primary: Change From Baseline in Volumetric Magnetic Resonance Imaging (vMRI) - Brain Boundary Shift Integral (BBSI) and Ventricular Boundary Shift Integral (VBSI) — 6.349…

Primary: Maximum Observed Plasma Concentration of Hyoscine Butylbromide (Cmax) — 91; 80 picogram (pg)/millilitre (mL)